Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans

[1]  J. Kublin,et al.  Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination , 2019, PloS one.

[2]  Allan C. deCamp,et al.  Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. , 2019, The Journal of clinical investigation.

[3]  J. Kublin,et al.  Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa , 2019, Science Translational Medicine.

[4]  D. Montefiori,et al.  Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period , 2019, The Journal of infectious diseases.

[5]  B. Pulendran,et al.  Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. , 2019, JCI insight.

[6]  Daniel W. Kulp,et al.  Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers , 2019, Immunity.

[7]  S. Kent,et al.  The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. , 2018, AIDS research and human retroviruses.

[8]  Valentine Wanga,et al.  Covariate‐adjusted Spearman's rank correlation with probability‐scale residuals , 2018, Biometrics.

[9]  Jerome H. Kim,et al.  Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations , 2018, PloS one.

[10]  N. Haigwood,et al.  Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges , 2018, Journal of Virology.

[11]  Jerome H. Kim,et al.  HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis , 2018, Journal of Virology.

[12]  R. Ruprecht,et al.  Mucosal IgA Responses: Damaged in Established HIV Infection—Yet, Effective Weapon against HIV Transmission , 2017, Front. Immunol..

[13]  B. Korber,et al.  Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail , 2017, Science Translational Medicine.

[14]  D. Montefiori,et al.  Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults , 2017, PloS one.

[15]  P. Boyaka.  Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems , 2017, The Journal of Immunology.

[16]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[17]  S. Kent,et al.  A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens , 2017, Front. Immunol..

[18]  S. McCormack,et al.  A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes , 2017, Front. Immunol..

[19]  F. Conejero-Lara,et al.  Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates , 2017, Front. Immunol..

[20]  D. Burton,et al.  Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus , 2016, Science.

[21]  J. Kublin,et al.  Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants , 2016, PloS one.

[22]  H. Liao,et al.  Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses , 2016, PLoS pathogens.

[23]  S. McCormack,et al.  Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study , 2016, PloS one.

[24]  Vicki C. Ashley,et al.  Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women , 2016, AIDS.

[25]  T. Kepler,et al.  Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies , 2015, Science.

[26]  Jerome H. Kim,et al.  Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques , 2015, PLoS pathogens.

[27]  Q. Sattentau,et al.  Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. , 2015, Vaccine.

[28]  Jennifer A. Johnson,et al.  Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. , 2015, The Journal of infectious diseases.

[29]  G. Gray,et al.  Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa , 2014, PloS one.

[30]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[31]  H. Liao,et al.  HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities , 2014, PloS one.

[32]  J. Hoxie,et al.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.

[33]  S. Hammer,et al.  Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. , 2014, The Journal of infectious diseases.

[34]  Jerome H. Kim,et al.  Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide , 2014, Journal of Virology.

[35]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[36]  H. Liao,et al.  Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity , 2014, Journal of Virology.

[37]  O. Yang,et al.  Differential Blood and Mucosal Immune Responses against an HIV-1 Vaccine Administered via Inguinal or Deltoid Injection , 2014, PloS one.

[38]  S. Zolla-Pazner,et al.  Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques , 2013, Mucosal Immunology.

[39]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[40]  Q. Sattentau,et al.  Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission , 2013, AIDS.

[41]  Jerome H. Kim,et al.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG , 2013, Proceedings of the National Academy of Sciences.

[42]  Jerome H. Kim,et al.  Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees , 2013, Journal of Virology.

[43]  Haiyan Chen,et al.  Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk , 2013, Journal of Virology.

[44]  L. Lopalco,et al.  Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes , 2013, PloS one.

[45]  W. Blattner,et al.  HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life , 2013, Mucosal Immunology.

[46]  D. Burton,et al.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.

[47]  D. Montefiori,et al.  A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. , 2011, The Journal of infectious diseases.

[48]  S. Jeffs,et al.  Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses , 2010, Mucosal Immunology.

[49]  Z. Hel,et al.  Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. , 2009, Journal of reproductive immunology.

[50]  G. Andrews,et al.  Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses , 2009, Vaccine.

[51]  Pascal Poignard,et al.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.

[52]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[53]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[54]  J. Mestecky,et al.  Human Male Genital Tract Secretions: Both Mucosal and Systemic Immune Compartments Contribute to the Humoral Immunity1 , 2005, The Journal of Immunology.

[55]  J. Woof,et al.  Mucosal immunoglobulins , 2005, Immunological reviews.

[56]  M. McElrath,et al.  Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. , 2004, The Journal of infectious diseases.

[57]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[58]  L. Lopalco,et al.  Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells1 , 2000, The Journal of Immunology.

[59]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[60]  H. Staats,et al.  Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. , 1997, AIDS research and human retroviruses.

[61]  L. Bélec,et al.  Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination , 1994, Infection and immunity.